Elastagen is committed to becoming a valued and respected commercial organization developing safe and efficacious products to the highest quality for patients seeking cosmetic and medical dermatology procedures worldwide.
The Elastin technology was developed through nearly 20 years of research in the laboratories of Professor Anthony Weiss at the University of Sydney. Since licensing the technology, Elastagen has worked extensively with researchers, clinicians and product consultants in Europe, North America and Australia to further develop and refine the technology. Elastagen has an extensive intellectual property portfolio covering the production, formulation and application of Elastin.
As the world leaders in human Elastin technology, we are the first company to successfully scale up the production of clinical grade GMP manufactured recombinant human tropoelastin, the building block of Elastin. Elastagen operates in compliance with ISO13485 and 21CFR820 and our clinical trial activities are registered under the Australian TGA’s Clinical Trial Notification scheme and run in accordance with the ICH guidelines for Good Clinical Practice.
As we progress our products through the regulatory approval process, we will continue to place a strong emphasis on scientific and clinical excellence and look forward to introducing our promising Elastatherapy™ treatments to the cosmetic and medical dermatology markets worldwide.
|Dec ’11||Elastagen Strengthens Board with Appointment of Xavier Yon|
|Oct ’11||Elastagen Featured in Prime Magazine|
|Sep ’11||Elastagen Expands Clinical Program for Elastin Products|
|Dec ’10||Elastagen Initiates Clinical Testing of Elastin Products|
|Dec ’09||Skin Elastin Products A Significant Step Closer|
|Feb ’11||The Science of Elastin|